

Minutes: Steering Board meeting, 13 November 2020

2. Update on contracts

This session was dedicated to a comprehensive presentation of the **CureVac** APA.

Key elements of the contract were presented and explained in great detail to the members.

Elements illustrated include:

- information about the characteristics of the vaccine (dosage);
- number of doses;
- price , upfront payment and payment schedule;
- delivery schedule;
- delivery condition (temperature, shelf life)
- resale and donation clause;
- liability and indemnification provisions;
- termination clauses etc.

The Members were reminded about the **confidentiality** rules regarding the information from the contracts.

The Members were also reminded about the importance of finalising the **ESI process**, in order to be able to as agreed.

3. COVAX

The Members were invited to comment on three issues and [REDACTED]

[REDACTED] :

- [REDACTED]

- [REDACTED]

It was outlined that :

- the Executive Committee, a sub-group of the Shareholders Council was set up with 12 participants, 3 per WHO region;
- the Shareholders Council invited each of the four WHO regions to nominate three participants;
- the EU represented the biggest part of the European region and was the largest donor to COVAX;
- the Shareholders Council was also invited to nominate two co-chairs.

- M-RNA vaccines in COVAX portfolio

It was explained that :

- at the Shareholders Council meeting on 2 November, participants received information on cost, regulatory approval and logistical implications of m-RNA vaccines in the COVAX portfolio (so far BionTech/Pfizer and Moderna);
- [REDACTED]

Regarding **donations**, it was underlined that EU should lead by example and [REDACTED] trigger other countries to take the same approach.

It was also outlined that vaccines were purchased jointly at EU level, an EU coordinated approach regarding donation was therefore necessary.

The question of ESI funding in the context of donations was raised. [REDACTED]